Aortic & peripheral vascular disease
Identifying the highest risk vascular patients: Insights from the XATOA registry
Authors' conclusion
Patients with polyvascular disease represent a substantial subset of patients in clinical practice
Study context
- Population
- Patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) initiated on low dose rivaroxaban (2.5 mg BID) and aspirin5,532 in full analysis
- Participants
- 5,808 patients
- Exposure
- Polyvascular vs nonpolyvascular disease
- Polyvascularn = 2,889
- Outcome
- Incidence risk of major adverse cardiovascular events (MACE) or major adverse limb events (MALE)
- Follow-up
- Median 462 (IQR 371-577) days
Methodological detailsEnrolment November 2018 to May 2020
- Enrolment November 2018 to May 2020
Main finding
As reported in the abstract
MACE or MALE
Observational data: associations, not effects.
Safety
- Rates of major bleeding low overall
Original publication
Identifying the highest risk vascular patients: Insights from the XATOA registry. Am Heart J. Published 12 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →